Search is on for cases of aggressive, ruxolitinib-associated skin cancers
April 30, 2016|Hematology and Oncology
Author and Disclosure Information
AT THE ACMS ANNUAL MEETING
“He was already immunosuppressed from his malignancy. He was on hydroxyurea, a drug that’s a cumulative phototoxin, and he’s out in the sun playing golf every day, and then was put on ruxolitinib. But the question we face now is how to try and stop this medication so we can get better treatment for him which will, of course, be very difficult.”
To contribute to Dr. Zwald’s case series, please email her at Fiona.Zwald@gmail.com.
She had no relevant financial disclosures.
On Twitter @Alz_Gal
